Studies s uggest t hat pr e-administration o f d ocetaxel ( DOC) in a driamycin ( ADR)-DOC combination anticancer therapy results in stronger antitumor effects and fewer ADR-induced cardiotoxic d eaths in m ouse model, yet no m echanism explaining t his ef fect h as b een established. The a im o f th is s tudy was to identify cellular p rocesses in mouse heart tis sue affected b y different ADR/DOC dosing pr otocols using a t oxicoproteomic a pproach. We applied f luorogenic-derivatization liq uid c hromatography ta ndem mass s pectrometry (FD-LC-MS/MS) -which consists of fluorogenic derivatization, separation and fluorescence detection b y LC, and i dentification b y LC-tandem m ass s pectrometry -to the proteomic analysis o f h eart t issue from control, intermittent-dosing (DOC-ADR), and s imultaneous -dosing (ADR&DOC) groups.
Introduction
Although adriamycin (ADR) is an anthracycline anticancer drug that has been widely applied in treating a range o f cancers (e.g., lymphoma, leukemia, breast cancer, and ovarian cancer), severe c ardiotoxicity a nd he art f ailure have be en obs erved i n ADR-treated can cer patients [1] . I n clinical tr ials for metastatic b reast can cer, an ADR an d d ocetaxel ( DOC) combination t herapy is m uch m ore ef fective t han t he previous c ombination t herapies (i.e., ADR-cyclophosphamide and fluorouracil-ADR-cyclophosphamide) [2, 3] . However, severe toxicities including m yelosuppression and cardiotoxicity limit the clinical use of ADR/DOC combination therapy in many patients with breast cancer [2] [3] [4] .
Many attempts have been made to reduce the adverse effects induced b y anticancer drugs, and on e s uch a pproach ha s be en c hronotherapy. Chronotherapy i s de fined a s t he administration o f me dications u sing biological rhythms to o ptimize therapeutic outcomes and/or control adverse effect. The chronopharmacology of many antitumor drugs have been studied in human and animals specifically to decrease adverse effects [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The individual toxicities of ADR and DOC apparently depend on dos ing time in animals and human [8] [9] [10] [11] [12] [13] .
Among the chronopharmacologic studies, To and colleagues reported that the DOC-pretreated group, in which ADR was administered 12 h after DOC injection, exhibited not only stronger inhibition of t umor g rowth but a lso a significant reduction in cardiotoxic d eaths compared with a ll th e o ther c o-administration groups and with the ADR-alone group in mic e [14] .
This remarkable finding has been subsequently studied in detail using mouse models [15, 16] , and t he r eduction i n t oxic de ath w as f ound t o b e DOC dose-dependent [ 16] ; how ever, no 5 mechanism explaining the effect of DOC pre-administration has been established.
Proteomics is th e la rge-scale s tudy o f gene e xpression at t he p rotein l evel an d provides i nformation on d ynamic c ellular pe rformance. As an i ntegration of pr oteomics, toxicology, and bioinformatics, toxicoproteomics mainly focuses on protein changes in cells or tissues with exposure to toxicants, including antitumor drugs [17, 18] .
In p roteomic s tudies, comparative ex pression profiling of proteins has usually be en performed using two-dimensional electrophoresis (2-DE) because this has been the method of choice. However, the 2-DE method has some drawbacks with regard to the reproducibility of t he d ata. Importantly, 2-DE often c annot r eproducibly resolve minute d ifferences i n protein e xpression levels between s amples from di fferent t reatment groups. In an e ffort t o overcome the limitation of 2-DE, Imai and colleagues developed an e asily reproducible and highly s ensitive proteomic a pproach, fluorogenic d erivatization-liquid c hromatography tandem m ass s pectrometry (FD-LC-MS/MS) method [ 19, 20] . This m ethod i nvolves fluorogenic derivatization of proteins, followed by high pe rformance l iquid chromatography (HPLC) of t he de rivatized pr oteins, i solation of t hose pr oteins with differential expression between the treatment groups, enzymatic digestion of the isolated proteins, and identification of the isolated proteins utilizing LC-tandem MS with a d atabase-searching algorithm. This method e nables hi ghly sensitive d etection and high resolution of p roteins a t th e femtomol level due t o t he f luorogenic de rivatization w hich ut ilizes a non -fluorescent r eagent t o yield highly fluorescent products. The applicability o f the method has be en d emonstrated i n t he analyses of extracts from Caenorhabditis elegans, mouse liver, breast cancer cell lines, mouse 6 brain, and t horoughbred hor se s keletal m uscle, r evealing t he pr oteins r elated t o early s tage Parkinson's disease, hepatocarcinogenesis, metastatic breast cancer, aging, and training effects, respectively [21] [22] [23] [24] [25] [26] .
The a im o f th is study was to identify the cellular p rocesses a ffected b y t he pre-administration o f D OC in ADR/DOC combination therapies using a toxicoproteomic approach based o n FD-LC-MS/MS. The pr esent s tudy r eported t he di fferential a nalysis of mouse h eart tis sues isolated f rom control, in termittent-dosing ( DOC-ADR), a nd simultaneous-dosing (ADR&DOC) groups.
Material and methods

Preparation of dosing drugs
ADR, supplied by Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Japan), was dissolved in saline; t he co ncentration w as 2 mg /ml. DOC ( Taxotere ® , S anofi-aventis, B ridgewater, N J, USA) was dissolved in ethanol; 5% glucose in water was added to obtain the ratio of ethanol and glucose solution (3:97, v/v) and the final concentration of DOC was 1.25 mg/ml
Animal treatment and tissue processing
Male ICR m ice ( 5-weeks ol d) w ere pur chased f rom Japan S LC ( Nagasaki, Japan). (Fig. 1 ). The ADR dose had been shown to be cardiotoxic in mouse [27] . The DOC dose had been shown to provide the strongest cardioprotection in the intermittent-dosing m ouse g roup [16] . Also, w hen dos ing i ntervals ( 6, 12, 24 h) be tween DOC and ADR treatments were changed, 12-h interval group showed the lowest toxic death rate [16] . Heart samples were isolated from all mice 1 week after ADR was administered in the ADR&DOC and D OC-ADR gr oups. All h eart s amples w ere imme diately rinsed w ith phosphate buf fer s aline and f rozen at -196°C. All h eart s amples were homogenated using the Frozen Cell Crasher (Microtec Co., Ltd., Chiba, Japan). At least four mice were used in each ex perimental group (i.e., c ontrol, D OC-ADR a nd ADR &DOC), and al l data was subjected to statistical analysis. FDR was calculated using the number of significant unique peptide in the reversed database divided by the number of those in the forward database. Proteins were identified with more than two peptides ≥ 6 amino acids long. A low probability suggests a good match in that it indicates that the match between the sequence an d the spectrum could not easily happen b y accident. If multiple proteins shared amino acid sequences with found peptides, the protein with th e lo west p robability among th em w as d etermined to b e th e mo st lik ely ma tch, and ubiquitous keratins and trypsin were excluded as potential matches.
Preparation of samples and determination of total proteins
FD-LC-MS/MS method
Statistical analysis
Results ar e ex pressed as t he m ean ± standard de viation. Differences b etween t he groups w ere d etermined b y Tukey-Kramer m ultiple c omparison te st. P < 0.05 was considered to be significant.
Results
Analytical performance of FD-LC-MS/MS method
The total protein amount required for quantification was 8.7 µg per HPLC injection.
The precision of the method was confirmed based on t he reproducibility of the peak heights using f our p eaks, including hi gh, m edium, and l ow pe aks. The r elative standard de viation 12 (RSD, %) values were i n t he range of 6.6 -11.9% fo r between-days ( n = 5) replicates. The reproducibility o f th e r etention time s u sing s ame p eaks was a lso c alculated, and t he between-day RSD values were less than 0.82% (n = 5). 
Differential profiling and protein identification
Discussion
In our pre-clinical (mouse) study [14] , the DOC-ADR group showed a significantly 13 higher survival rate compared with the ADR&DOC group (P < 0.01), and the survival rates on da y 35 w ere 86.2 % in t he D OC-ADR group a nd 22.2 % i n t he A DR&DOC group. A subsequent study r evealed t hat the t oxic d eath of m ouse was a ttributed to cardiotoxicity induced by ADR [16] . Therefore, in this study, the differential proteomic profiling of mouse heart tissues from DOC-ADR, ADR&DOC, and control groups was performed to identify the proteins that mediate the cardioprotective effect of DOC pretreatment in the DOC-ADR group.
Significant Q T i nterval prolongation of m ouse was obs erved 1 week af ter A DR-treatment, compared with non-treated mouse; therefore, 1 week after drug treatment was chosen for the toxicoproteomic analysis. Based o n the h igh s ensitivity, r esolution, and r eproducibility, ni ne pr oteins w ere found t o be differentially expressed between t he t hree groups, seven of which were t he proteins involved i n e nergy pr oduction processes, the glycolytic pa thway, the tricarboxylic acid ( TCA) cycle, and the electron t ransport ch ain as s hown i n F ig. 3 . Among t he differentially expressed proteins, aconitase (peak no. 11) was the most drastically reduced in this study and has been reported to be inactivated b y ADR treatment [33, 34] . A lso, Ldha protein ( peak no. Therefore, these results ensured the validity of FD-LC-MS/MS as a toxicoproteomic method.
Most of t he differentially ex pressed proteins identified i n our s tudy are i nvolved i n the myocardial energy network. Heart muscle requires large amounts of energy to sustain its contractile performance; therefore, cellular energy deficits are recognized as an important and common f actor i n t he de velopment of cardiac m yopathies [35] [36] [37] . Adenosine [38] [39] [40] [41] [42] . These effects have been c onsistently o bserved i n pa tients t reated w ith ADR [43] .
Evidence h as accumulated i ndicating a relationship b etween m yocardial energy m etabolism
and ADR-induced cardiotoxicity [44] .
Among the six proteins that were differently expressed between t he dos ing groups, four were more highly expressed in the ADR&DOC group than in the DOC-ADR group (peak nos. 10, 11, 16, and 19) . Based on t heir high expression levels in the ADR&DOC group, it was assumed that the activated energy production contributed to enhance cardiac contractile force and m aintain t he f unction. However, t he elevated expression obs erved i n t he ADR&DOC group did not lead to an increase in survival rate in the combination therapy. In other w ords, t he l ower expression of t he f our proteins i n the DOC-ADR g roup di d not adversely a ffect s urvival. F urthermore, although t he e xpression of T CA c ycle enzymes (peak nos. 11 and 16) in the DOC-ADR group was significantly lower than those in control group, a higher survival rate was observed in DOC-ADR group than in the ADR&DOC and ADR-only t reatment groups [14, 16] . Therefore, t he alteration o f t hese four proteins ma y not be a definitive factor for cardioprotective effect of DOC-pretreatment.
GAPDH c atalyses t he nicotinamide adenine di nucleotide-dependent conversion of glyceraldehyde-3-phosphate i nto 1,3 -diphosphoglycerate. It i s t he f irst e nergy-harvesting enzyme an d a central p layer i n g lycolytic p athway, placing it at t he c ore o f c ancer cel l survival [45] . Generally, GAPDH is considered a hous ekeeping e nzyme be cause i t is constitutively expressed in most tissues an d cel l t ypes. However, s everal r eports r evealed that it is differentially regulated by circadian clock or in disease states [46, 47] . The highly 16 elevated expression o f GAPDH i n the DOC-ADR g roup may be important in maintaining cardiac function after combination t herapy and result i n hi gher s urvival r ates. It is unclear whether al l glycolysis-dependent e nergy s upply is increased by elevated ex pression o f GAPDH because t he ex pression o f another glycolytic en zyme, al dolase, w as l ower in t he DOC-ADR g roup than i n the ADR&DOC group. However, i t was reported t hat ADR induced a decrease in ATP content in endothelial cell, which was paralleled by a decrease in GAPDH activity [48] . Therefore, to some extent, the elevated expression of GAPDH in the high cellular energy state in the DOC-ADR group relative to the control group; although the expression was found not to be significantly different between the two dosing groups.
To date, two papers have reported proteomic studies of ADR-induced cardiotoxicity and the mechanism against it [56, 57] . On one hand, redox proteomics was performed based on the hypothesis that the cardiotoxic actions of ADR are caused by the oxidative stress [56] .
However, that approach may b e insufficient to reveal alterations in protein e xpression in important cellular p rocesses because i t f ocuses on identifying only the oxidatively modified proteins. Using a di fferent a pproach, Kang and co lleagues i dentified d ifferences i n g lobal proteomic profiles of heart tissue between non-transgenic (TG) and TG mice that over-express metallothionein to understand the molecular mechanism of metallothionein protection against ADR-induced cardiotoxicity [57] . They found elevated expression of cytochrome c oxidase subunit Va, w hich regulates ox idative phos phorylation, i n T G m ouse he art i n r esponse t o ADR treatment. In the present study, the highly sensitive proteomic analysis of heart tissues suggests th at G APDH ma y counteract ADR-induced c ardiotoxicity. GAPDH i s a multifunctional protein, pa rticipating i n energy s upply and antioxidative a ctivity; t herefore any or all of GAPDH's functions may be relevant to the cardioprotective effects observed in the DOC-ADR treatment group. However, it was not yet clear exactly what mechanism was responsible for either the cardioprotective effects or the over-expression of GAPDH observed 18 in the DOC -ADR group. Previous r esearch ha s s hown t hat the over-expression of antioxidant e nzymes (i.e., superoxide d ismutase and c atalase) in TG mice protected heart from A DR-induced cardiotoxicity [ 58, 59] . Therefore, the s ame transgenic approach or another approach with the addition of N 6 -naphthalenemethyl-2'-methoxybenzamido-β-NAD + for GAPDH inhibition [60] may be useful in validating and elucidating any cardioprotective effects associated with GAPDH. Further analysis of GAPDH is necessary to determine if it is a potential target for protective intervention against ADR-induced cardiotoxicity.
In summary, i n or der to better u nderstand t he car dioprotective effect o f pre-administration of DOC in an ADR/DOC combination anti-cancer therapy, we applied the FD-LC-MS/MS me thod to d ifferential p roteomic a nalysis o f heart tis sues from control, intermittent-dosing and s imultaneous-dosing groups of mice. This highly reproducible and sensitive method id entified s ignificantly a ltered expression of ni ne proteins i n m ouse he art, and seven of these proteins ar e involved i n t he c ellular e nergy production. Significantly elevated expression of GAPDH was observed in the DOC-ADR group, in which the survival rate was higher [14, 16] , than the ADR&DOC group. Therefore, GAPDH may be developed as a pot ential t arget f or pr otective i ntervention a nd a biomarker f or e valuation of cardioprotective effect of experimental treatments in pre-clinical studies. Fig. 3 (continued) 
Figure captions
